The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing–remitting multiple sclerosis
Restricted accessResearch articleFirst published online February, 2012
The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing–remitting multiple sclerosis
Background: The intrathecal production of immunoglobulin (Ig) is a major biological feature of multiple sclerosis (MS), and immunopathological studies have suggested a primary role of the humoral immune response in causing irreversible brain damage.
Objective: To evaluate whether, in the early phases of MS, intrathecal Ig synthesis correlates with the presence of cortical lesions (CLs), and if their association could predict the clinical course of the disease.
Methods: Eighty-six patients presenting with symptoms and signs suggestive of MS underwent a diagnostic work-up that included magnetic resonance imaging and cerebrospinal fluid examination. The risk ratios (RR) for conversion to MS and for a new disease activity were calculated.
Results: Patients with clinically isolated syndromes (CIS) having CLs and intrathecal synthesis of Ig had the highest risk of conversion to MS (RR = 3.4; Wald 95% CI = 1.7–7.0, p < 0.001) whereas CIS patients without CLs and intrathecal synthesis of Ig had the lowest risk of conversion to MS (RR = 0.1, Wald 95% CI = 0.02–0.7, p < 0.001). The highest risk of having disease-related activity during the follow-up was observed in CIS and relapsing–remitting MS patients showing CLs and intrathecal Ig synthesis (RR = 2.1; Wald 95% CI = 1.5–3.1, p < 0.001) while the lowest in CIS and relapsing–remitting MS patients without CLs and intrathecal Ig synthesis (RR = 0.3; Wald 95% CI = 0.1–0.7, p < 0.001).
Conclusion: We observed that the association of intrathecal immunoglobulin synthesis and CLs was highly predictive of an earlier CIS conversion to MS as well as of a higher disease activity.
KapposLFreedmanMSPolmanCH. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet2007; 370: 389–397.
2.
ClericoMFaggianoFPalaceJRiceGTintorèMDurelliL. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev2008; April16(2): CD005278.
3.
O’RiordanJIThompsonAJKingsleyDP. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain1998; 121(Pt 3): 495–503.
4.
BrexPACiccarelliOO’RiordanJISailerMThompsonAJMillerDH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med2002; 346: 158–164.
5.
PolmanCKapposLFreedmanMS. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. J Neurology2008; 255: 480–487.
6.
LebrunCBensaCDebouverieM. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol2009; l; 66: 841–846.
7.
SwantonJKFernandoKTDaltonCM. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler2010; 16: 156–165.
8.
TintorèMRoviraARioJ. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?Neurology2008; 70(13, Pt 2): 1079–1083.
9.
AwadAHemmerBHartungHPKieseierBBennettJLStuveO. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol2010; 219: 1–7.
10.
RojasJIPatruccoLCristianoE. Oligoclonal bands and MRI in clinically isolated syndromes: predicting conversion time to multiple sclerosis. J Neurol2010; 257: 1188–1191.
11.
VillarLMMasjuanJGonzález-PorquéP. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology2002; 59: 555–559.
12.
VillarLMMasjuanJGonzález-PorquéP. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol2003; 53: 222–226.
13.
VillarLMSádabaMCRoldánE. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest2005; 115: 187–194.
14.
PeriniPRanzatoFCalabreseMBattistinLGalloP. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J Neurol Neurosurg Psychiatry2006; 77: 953–955.
15.
KiddDBarkhofFMcConnellRAlgraPRAllenIVReveszT. Cortical lesions in multiple sclerosis. Brain1999; 122(Pt 1): 17–26.
16.
PetersonJWBöLMörkSChangATrappBD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol2001; 50: 389–400.
17.
GeurtsJJPouwelsPJUitdehaagBMPolmanCHBarkhofFCastelijnsJA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion–recovery MR imaging. Radiology2005; 236: 254–260.
18.
CalabreseMDe StefanoNAtzoriM. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol2007; 64: 1416–1422.
19.
CalabreseMAtzoriMBernardiV. Cortical atrophy is relevant in multiple sclerosis at clinical onset. JNeurol2007; 254: 1212–1220.
20.
FilippiMRoccaMACalabreseM. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology2010; 75: 1988–1994.
21.
CalabreseMRoccaMAAtzoriM. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol2010; 67: 376–383.
22.
CalabreseMAgostaFRinaldiF. Cortical lesions and atrophy associated with cognitive impairment in relapsing–remitting multiple sclerosis. Arch Neurol2009; 66: 1144–1150.
23.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
24.
McDonaldWICompstonAEdanG. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50: 121–127.
25.
PolmanCHReingoldSCEdanG. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol2005; 58: 840–846.
26.
GiovannoniGCookSRammohanKRieckmannP. Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol2011; 10: 329–337.
27.
ReiberHPeterJB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci2001; 184: 101–122.
28.
ReiberHAlbaumW. Statistical evaluation of intrathecal protein synthesis in CSF/Serum quotient diagrams. Acta Neuropsychiatrica2008; 20: 48–49.
29.
MeadRJSinghraoSKNealJWLassmannHMorganBP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol2002; 168: 458–465.
30.
HuWLucchinettiCF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol2009; 31: 439–453.
31.
BerlandRWortisHH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol2002; 20: 253–300.
32.
VillarLMEspiñoMCavanillasML. Immunological mechanisms that associate with oligoclonal IgM band synthesis in multiple sclerosis. Clin Immunol2010; 137: 51–59.
33.
MagliozziRHowellOVoraA. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130(Pt 4): 1089–1104.
34.
SerafiniBRosicarelliBMagliozziRStiglianoEAloisiF. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol2004; 14: 164–174.
35.
GeurtsJJRoosendaalSDCalabreseM. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology2011; 76: 418–424.
